Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer
Breast Cancer · 2025
DOI: 10.1007/s12282-025-01694-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer, 2025. Verfasst von Mao Uematsu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm, Residual, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The area of residual tumor (ART) is a quantitative method for assessing tumors after neoadjuvant chemotherapy (NAC). This study evaluated whether ART can identify a favorable prognosis group in patients with HER2-positive surgically resected breast cancer and residual tumors post-NAC.
Methods
We retrospectively reviewed patients with HER2-positive who underwent surgery after NAC, including trastuzumab, from 2005 to 2022 at our institution. ART was assessed at the maximum cut surface of the residual primary tumor using digital pathology images. Receiver operating characteristic curve analysis determined ART-Low and ART-High cutoffs, excluding ART-0 (0 mm 2 ) patients.
Results
Of the 219 patients, 82 had ART greater than 0 mm 2 . The median follow-up was 90.2 months. The number of patients in the ART-0, ART-Low (0 < ART ≤ 4.0 mm 2 ), and ART-High (> 4.0 mm 2 ) groups were 137, 39, and 43, respectively. The ART-Low group showed significantly shorter event-free survival compared to the ART-0 group (HR 3.50, 95% CI 1.52–8.06), and the ART-High group also tended toward poorer prognosis (HR 2.31, 95% CI 0.89–5.97). However, there was no significant difference in prognosis between the ART-Low and ART-High groups.
Conclusions
The current study suggests that even minimal residual tumor cells in the primary site can significantly impact on prognosis in HER2-positive early breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
- Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Bunkyō, Japan.
- Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan. hiromina@east.ncc.go.jp.
- Department of Experimental Therapeutics, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan. hiromina@east.ncc.go.jp.
- Department of General Internal Medicine, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan. hiromina@east.ncc.go.jp.
- Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
Zitieren
APA
Uematsu, M., Nakajima, H., Miyake, H., Wakabayashi, M., Funasaka, C., Kondoh, C., Harano, K., Matsubara, N., Hosono, A., Naito, Y., Sakamoto, N., Kojima, M., Onishi, T., Ishii, G., & Mukohara, T. (2025). Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer. Breast Cancer. https://doi.org/10.1007/s12282-025-01694-7
Vancouver
Uematsu M, Nakajima H, Miyake H, Wakabayashi M, Funasaka C, Kondoh C, et al. Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer. Breast Cancer. 2025. doi:10.1007/s12282-025-01694-7
BibTeX
@article{Uematsu2025,
author = {Uematsu, Mao and Nakajima, Hiromichi and Miyake, Hirohiko and Wakabayashi, Masashi and Funasaka, Chikako and Kondoh, Chihiro and Harano, Kenichi and Matsubara, Nobuaki and Hosono, Ako and Naito, Yoichi and Sakamoto, Naoya and Kojima, Motohiro and Onishi, Tatsuya and Ishii, Genichiro and Mukohara, Toru},
title = {Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer},
journal = {Breast Cancer},
year = {2025},
doi = {10.1007/s12282-025-01694-7}
}
EUVIMED